Comparative Pharmacology
Head-to-head clinical analysis: FEMARA versus TESLAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMARA versus TESLAC.
FEMARA vs TESLAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aromatase inhibitor; inhibits the conversion of androgens to estrogens by competitively binding to the aromatase enzyme, thereby reducing estrogen levels in peripheral tissues and tumors.
Androgen receptor inhibitor; suppresses gonadotropin secretion and reduces testosterone levels.
2.5 mg orally once daily.
250 mg intramuscularly three times per week
None Documented
None Documented
The terminal elimination half-life of letrozole is approximately 2 days (range 24–48 hours). Steady-state concentrations are achieved within 2–6 weeks of daily dosing. The long half-life supports once-daily dosing.
Terminal half-life approximately 2-4 hours; clinical significance: requires multiple daily dosing for steady-state maintenance.
Letrozole is extensively metabolized in the liver, primarily to an inactive carbinol metabolite. Approximately 90% of an oral dose is excreted in urine, with about 6% as unchanged drug and 84% as metabolites. Fecal excretion accounts for less than 10%.
Renal (primarily as metabolites) and biliary/fecal. The drug is extensively metabolized; less than 5% is excreted unchanged in urine.
Category C
Category C
Aromatase Inhibitor
Aromatase Inhibitor